slx4090
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2007 (NCT00562575)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
Microsomal triglyceride transfer protein inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 6-(4'-trifluoromethyl-6-methoxybiphenyl-2-ylcarboxamido)-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid phenyl ester
- slx4090
- slx 4090
- slx-4090
- slx-4090
- slx-4090
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01675154 | Phase 2 | Nov 1, 2015 | The University of Texas, Dallas |
| NCT00871936 | Phase 2 | Apr 1, 2009 | Kadmon |
| NCT00810979 | Phase 2 | Jan 1, 2009 | Kadmon |
| NCT00562575 | Phase 2 | May 1, 2007 | Kadmon, Nuvisan Pharma Services |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kadmon | For profit | 3 | 3 | 1 | 2007 |
| Nuvisan Pharma Services | For profit | 1 | 0 | 1 | 2007 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 1 | 1 | 2015 |
3 organizations
Page 1 / 1